Ukrainian battlefield testing of bioengineered human tissue to treat vascular injuries has shown positive results, with no patients suffering infections or amputations after wounds from bullets, mines or shrapnel, said Humacyte, the biotech company developing the treatment, known as ATEV.
An initial 30-day follow-up on 16 Ukrainians treated with ATEV, which stands for Acellular Tissue Engineered Vessel, showed a 93.8% success rate in maintaining blood flow with no amputations or infections, the company said.
